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INSURANCE COVERAGE FOR CANCER TREATMENT-
INDUCED CONDITIONS: COMPARING FERTILITY
PRESERVATION TECHNOLOGY AND BREAST
RECONSTRUCTIVE SURGERY
Lisa Campo-Engelstein*
I. INTRODUCTION
There is much debate not only about the morality of assisted repro-
ductive technologies (ART), but also about how they should be classi-
fied. Should ART be understood as medical treatment for a disease
(infertility), or should these technologies be relegated to boutique
medicine where they are seen as elective? How we answer this ques-
tion affects our thoughts about whether ART should be covered by
insurance companies. Those who claim infertility is a medical disease
usually advocate that ART be covered by insurance. Conversely,
those who believe ART are elective procedures generally oppose in-
surance coverage, insisting that insurance coverage should be limited
to medically necessary treatments. While the debate cannot simply be
reduced to whether "real" diseases should be covered by insurance
and all other conditions should not, in the minds of many, a strong
connection exists between what is considered a disease and what in-
surance should cover. For the purposes of this Commentary, there-
fore, the belief that medically necessary procedures should be covered
by insurance-whereas elective procedures should not-will serve as
the basis of the discussion.
Most discussions of ART focus on their use in two circumstances.
The first is to treat people currently suffering from infertility due to
disease (such as endometriosis) or some unknown cause. The second,
and more recent, is to provide "insurance" against age-related infertil-
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ity for women who plan to delay childbearing. Though still a conten-
tious issue, the former-disease-induced infertility-is typically
thought to be more deserving of insurance coverage than the latter-
age-related infertility-because the cause of infertility is a disease, a
"legitimate" medical problem rather than an individual's conscious
decision. Indeed, some have argued that insurance should cover treat-
ment for the underlying disease that is causing infertility (such as open
a blocked fallopian tube) even if they do not think insurance should
cover ART.1 The perceived cause of age-related infertility is, in con-
trast, not often seen as legitimate, but rather as the result of a
woman's choices and selfishness. According to this view, a woman's
desire to have a career leads her to delay childbearing, which is no
one's fault but her own.2 In short, age-related infertility is not a medi-
cal problem and thus should not be covered by insurance.
Although this Commentary centers on infertility and insurance cov-
erage, it diverges from these other debates in two significant ways.
First, it will bypass the question of whether infertility should be classi-
fied as a disease. Second, it does not deal with disease-induced or age-
related infertility. Rather, it focuses on another circumstance in which
one might use ART: before undergoing necessary medical treatment
that may lead to infertility. Specifically, I am concerned with fertility
preservation procedures for cancer patients who are about to receive
chemotherapy or radiation, both of which often cause infertility. I will
refer to this type of infertility as iatrogenic infertility.
II. INSURANCE COVERAGE FOR IATROGENIC CONDITIONS
An iatrogenic condition is a negative side effect or adverse condi-
tion that is caused by the diagnosis, manner, activity, or treatment of a
health care provider. I recognize that this is a loaded term (which
insurance companies and providers typically prefer not to use), in part
because some see it as a normative term implying a provider's wrong-
doing and blame. While this term encompasses negligent iatrogenic
conditions, such as a surgeon leaving a scalpel inside the body of a
patient, this Commentary uses it to refer only to nonnegligent condi-
tions. Nonnegligent iatrogenic conditions occur when medically nec-
essary treatments have unavoidable or unpredictable negative side
effects, such as cancer treatment causing infertility, hair loss, or nau-
sea. Health care providers are not to blame in these situations, as they
1. Interview with Marybeth Gerrity, Director of the Oncofertility Consortium, Northwestern
Univ., in Chi., Ill. (June 2009).
2. See generally Imogen Goold & Julian Savulescu, In Favour of Freezing Eggs for Non-Medi-
cal Reasons, 23 BIOETHics 47 (2008) (discussing and arguing against this position).
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face a no-win situation: providers must harm their patients in order to
treat and hopefully save these patients' lives. Unfortunately, the na-
ture of certain cancer treatments, as well as various treatments for
other diseases, is inherently harmful (for example, it destroys healthy
cells along with cancerous ones).
Insurance companies generally cover treatment for iatrogenic con-
ditions that result from cancer treatment even though they do not
cover these same conditions when they are "naturally" occurring.
Infertility treatment, on the other hand, is typically not covered, re-
gardless of whether it is iatrogenic or naturally occurring. One reason
many insurance companies refuse to cover ART is that they are often
viewed as elective procedures, not medically necessary ones. How-
ever, based on insurance coverage patterns for other "elective" proce-
dures performed in response to iatrogenic conditions, insurance
companies should also cover ART, specifically fertility preservation
treatments (such as cryopreservation of eggs, embryos, or ovarian tis-
sue for later use) for female cancer patients. In this way, insurance
companies will maintain consistency and promote fairness because
fertility preservation does not differ significantly from other treat-
ments for iatrogenic conditions they already cover for women. While
my focus is on female fertility preservation, one could presumably
make a similar argument that male fertility preservation should be
covered by insurance.
In order to support this claim, I compare ART for iatrogenic infer-
tility to breast reconstruction surgery. When following a lumpectomy
or mastectomy, breast reconstruction is generally covered by insur-
ance. Just as in the case of infertility, there is probably not agreement
on whether breast construction surgery for women who naturally have
only one breast is medically necessary or elective. While having only
one breast is rarely (if ever) a naturally occurring condition, this com-
parison makes for a good thought experiment. I will briefly explore
the different ways of understanding and classifying this condition to
highlight the discord.
Most would agree that missing a breast is not a life-threatening situ-
ation. However, it would probably adversely affect a woman's quality
of life. For example, surveys have shown that the loss of a breast
makes women feel less feminine-that is, less of a "real" woman 3 -
and I imagine women born without a breast would have similar emo-
tions. Moreover, women without two breasts may also make others
3. See Demetris Stavrou et al., Quality of Life After Breast Cancer Surgery with or Without
Reconstruction, EPLASTY, 161, 164 (June 2, 2009), available at http://www.eplasty.com/index.php?
option=comcontent&view=article&id=294&catid=170:volume-09-eplasty-2009&Itemid=121.
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feel uncomfortable because these women do not have all the typical
feminine gender markers (for example, gender markers include
breasts, hips, long(er) hair, and a lack of facial hair). Indeed, the
social response to women with one or no breasts may mimic the social
response to people who are intersex, as their physical appearance does
not match the "normal" female or male body. Yet, some have argued
that the condition of intersex is largely a social-not a medical-prob-
lem because it generally does not cause any physical health problems
and instead causes strong cultural discomfort by blurring and confus-
ing the gender lines.4 Likewise, one could claim having only one
breast does not lead to physical health problems, only personal and
cultural angst; thus, it should not be understood as a disease in need of
surgery.
Those who support a narrow, scientific definition of disease based
on biological functioning may also agree that having only one breast
does not require treatment and may assert that this condition is just an
anomaly like six fingers. Objectivist perspectives on disease echo this
belief, insisting that not all anomalies are diseases: "to call something
a disease involves both a claim about the abnormal functioning of
some bodily system and a judgment that the resulting abnormality is a
bad one."5 According to this view, classifying a condition as a disease
is a normative claim, so determining whether having one breast is a
medical condition involves drawing on one's own subjective values
and judgments. Some may concur that having one breast engenders
social problems, not physical health problems, yet still view this condi-
tion as a disease in need of treatment. This claim relies on a broad
definition of health like the one used by the World Health Organiza-
tion: "Health is a state of complete physical, mental and social well-
being and not merely the absence of disease or infirmity." 6 Under
such a definition, having only one breast would be considered a condi-
tion that interferes with one's social and mental health and quality of
life. Consequently, it should receive treatment.
The above discussion shows that there is not consensus regarding
whether surgery for women who naturally have only one breast is
medically necessary or elective. The same is true for ART to treat
infertility; there is little agreement on whether these procedures are
4. See Alice Domurat Dreger, "Ambiguous Sex"-or Ambivalent Medicine? Ethical Issues in
the Treatment of Intersexuality, HASTINGS CENTER REP., May-June 1998, at 24, 27, 30.
5. Dominic Murphy, Concepts of Disease and Health, STAN. ENCYCLOPEDIA PHIL. (2008),
http://plato.stanford.edularchives/sum2009/entries/health-disease.
6. WORLD HEALTH ORG., BASIC DOCUMENTS 1 (47th ed. 2009) (Constitution of the World
Health Organization).
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medically necessary or elective. This similarity is important because,
while breast surgery is covered by insurance when iatrogenic, it is un-
likely that all insurance companies would cover this surgery when it is
naturally occurring. As such, even though ART are often not covered
due to differences in how infertility is understood and classified, insur-
ance companies should cover ART in cases of iatrogenic infertility be-
cause it promotes consistency and fairness.
However, the case for insurance coverage for iatrogenic infertility
using the above comparison may remain unconvincing due to the in-
frequency of women having only one breast. A more common condi-
tion for which there would probably be greater consensus about its
treatment as elective is asymmetrical breasts. While having only one
breast is rarely a naturally occurring condition, naturally occurring
breast asymmetry is quite common. Insurance companies rarely cover
surgery for naturally occurring asymmetrical breasts, and I imagine
most people would agree with this decision. Breast asymmetry is
rarely as conspicuous or socially isolating as having only one breast, so
it makes sense that it would rank lower on the list of conditions that
should be covered by insurance. Indeed, surgery to "remedy" breast
asymmetry is often put on par with other "purely" cosmetic proce-
dures, such as otoplasty for "protruding" ears and rhinoplasty for
"6overly large" or "overly wide" noses. In sum, while these procedures
can improve an individual's self-esteem and thus quality of life, they
are generally seen as elective.
While surgery for naturally occurring breast asymmetry is not gen-
erally covered by insurance companies, surgery to resolve breast
asymmetry that results from a lumpectomy is usually covered, imply-
ing that the procedure is medically necessary. Moreover, in the case
of iatrogenic breast asymmetry, this surgery is covered regardless of
whether the patient had symmetrical breasts beforehand. Likewise,
breast reconstruction surgery following a mastectomy is typically cov-
ered, despite the debate over whether breast construction surgery
should be covered for naturally occurring "missing" breasts.
The discrepancy in breast surgery coverage between iatrogenic and
naturally occurring conditions can be explained, at least in part, by
looking at causality. According to one view, iatrogenic conditions are
caused by the medical realm and therefore the medical realm-specif-
ically the insurance companies-should take financial responsibility
for alleviating or fixing them. In other words, because members of the
medical profession caused the harm-something they are not sup-
posed to do-the medical profession as a whole must take responsibil-
2012] 853
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ity for mitigating the harm.7 The same principles apply when
naturally occurring conditions are thought to be caused by bad luck
or, at times, by the individual herself. Since the medical realm is not
causally responsible for these naturally occurring conditions, one
could argue that they should not be financially responsible for them.
At play in this connection between causality and responsibility is the
static understanding of the body that dominates medicine and science.
Briefly, this is the idea that the body stays the same over time and that
disease is an aberration that must be eradicated to restore the body to
its "natural" and "normal" state. If any alterations occur in the pro-
cess of healing the body, health care providers should do their best to
fix them so that the person's body is as close as possible to her original
state when they are finished.
Congress passed certain laws to institutionalize the medical realm's
responsibility for iatrogenic harms. For instance, the Women's Health
and Cancer Rights Act, passed in 1998, mandates that health insur-
ance companies covering the costs of mastectomies for cancer patients
must also cover the costs of breast reconstruction for those patients.8
Health care providers and insurance companies sometimes assume re-
sponsibility for iatrogenic harms by the way they code for billing. For
example, breast reconstruction surgery following a mastectomy is
coded as cancer treatment rather than elective treatment. By allowing
treatments for iatrogenic conditions to be subsumed into the larger
category of disease treatment, insurance companies are tacitly ac-
cepting financial responsibility to cover these treatments. In addition
to breast reconstruction surgery, there are other treatments that may
not be covered by insurance when the disease is naturally occurring
(in part because treatment is not seen as medically necessary), but are
covered when iatrogenic; for example, wigs following cancer treat-
ment are usually covered, whereas wigs for thinning hair or "cos-
metic" reasons often are not.
The same pattern of insurance coverage seems to exist, though
more covertly, in the fertility and infertility realms. Although fifteen
states now have laws mandating that insurance companies cover infer-
7. The idea that the medical profession should take responsibility for any harm it engenders
dates back to the Hippocratic Oath. Today, this idea is implemented through insurance coverage
for iatrogenic conditions.
8. See Women's Health and Cancer Rights Act of 1998, Pub. L. No. 105-277, 112 Stat. 2681-
337 (codified at 29 U.S.C. § 1185b); see also U.S. DEPT OF LABOR, Your Rights After a Mastec-
tomy: Women's Health and Cancer Rights Act of 1998 (2009), http://www.dol.gov/ebsa/publica-
tions/whcra.html.
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tility treatment under certain circumstances, 9 many insurance compa-
nies refuse to cover naturally occurring infertility or fertility
preservation treatments. Insurance companies give multiple reasons
why ART should not be covered: infertility treatments are experimen-
tal; they do not treat an underlying disease, but rather produce a de-
sired outcome (a child); and they are an elective, not a medical,
procedure. 10 However, there is growing evidence that insurance com-
panies are covering iatrogenic infertility resulting from cancer treat-
ment." Although no formal studies have been done, anecdotal data
demonstrate that insurance companies will sometimes take financial
responsibility for iatrogenic infertility.
At the Oncofertility Consortium, female cancer patients have the
option to choose a fertility preservation method-embryo, egg, or
ovarian tissue cryopreservation-before beginning cancer treatment.
These fertility preservation treatments have been billed under a pri-
mary diagnosis of cancer and a secondary diagnosis of procreative
management. Although there have been many appeals and much ne-
gotiation, so far insurance companies have covered many of these
treatments for the Consortium's patients. Fertile Hope, a nonprofit
organization that provides reproductive information and support to
cancer patients and survivors, also notes that some cancer patients
have convinced their insurance companies to cover fertility preserva-
tion by noting that insurance companies cover side effects of all other
medically necessary cancer treatments and that infertility should not
be different.12
III. FIVE OBJECTIONS TO INSURANCE COVERAGE OF
IATROGENIC INFERTILITY
The trend toward covering ART for cancer patients with iatrogenic
infertility is a move in the right direction, as it creates consistency in
policy coverage instead of treating infertility differently than other ia-
trogenic conditions. However, some may argue that insurance compa-
nies should not cover these treatments because they differ in
significant ways from treatments for other iatrogenic conditions. The
9. Gwendolyn P. Quinn et al., State Laws and Regulations Addressing Third-Party Reimburse-
ment for Infertility Treatment: Implications for Cancer Survivors, 95 FERTILITY & STERILITY 72,
75 (2011).
10. See Note, In Vitro Fertilization: Insurance and Consumer Protection, 109 HARv. L. REV.
2092, 2096-97 (1996).
11. Interview with Kristin Smith, Fertility Preservation Patient Navigator, Oncofertility Con-
sortium. Northwestern Univ., in Chi., Ill. (Sept. 2011).
12. See Financial Assistance, FERTILE HOPE, http://www.fertilehope.org/financial-assistance/
index.cfm (last visited Feb. 15, 2012).
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following discussion will raise and respond to five objections to insur-
ance coverage of iatrogenic infertility.
First, some ART, particularly egg and ovarian tissue cryopreserva-
tion, are considered experimental procedures, whereas breast recon-
struction surgery is an established procedure. By practice, insurance
companies rarely cover experimental procedures. Although the
American Society for Reproductive Medicine still defines egg cry-
opreservation as experimental,13 this technology, especially egg freez-
ing using vitrification, is improving rapidly, and some in the scientific
community no longer view it as experimental.14 Additionally, egg and
ovarian tissue cryopreservation are the only available options for
young or single women to be able to have a child with a future part-
ner, not a sperm donor. Creating embryos, the only "mature" tech-
nology, runs the risk that the biological father could oppose transfer.
As a matter of social justice, fertility preservation options not requir-
ing sperm need to be available to women in order to ensure they will
be able to have a biological child and have that child with the man
they choose.
Second, insurance companies tend to cover iatrogenic conditions
that currently exist, like hair loss from chemotherapy, or that will al-
most certainly exist, like loss of an entire breast following a mastec-
tomy. Insurance companies do not traditionally cover conditions that
may or may not exist in the future, like infertility. Yet, a low
probability of occurrence should not lead providers to forgo prophy-
lactic procedures to avoid iatrogenic conditions. In fact, providers
typically provide treatments to prevent iatrogenic conditions that may
or may not occur, such as antiemetics for nausea and dental evalua-
tions for osteoradionecrosis. Health care providers often recommend
storing one's own blood as a prophylactic precaution in the case of an
emergency transfusion. Whether the stored blood will be used cannot
be predicted, but patients often want to be prepared for possible
"worst-case scenarios." Those who seek fertility preservation treat-
ment are similarly motivated as those who store blood: in one worst-
case scenario-where patients find themselves infertile after cancer
treatment-these patients have a reserve of gametes to use to have
biological children.
13. Age and Elective Egg Freezing: The Allure of Postponing Childbearing Waxes as Odds of a
Successful Outcome Wane, AM. Soc'Y FOR REPROD. MED. (Oct. 18, 2011), http://www.asrm.org/
news/article.aspx?id=7336&terms=(+%40Publish To+Both+Sites+or+%40Publish To+ASRM+
Only+)+and+age+and+elective.
14. See Mitch Leslie, Melting Opposition to Frozen Eggs, SCIENCE, Apr. 2007, at 388.
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While treatment for most iatrogenic conditions generally occurs
very soon or immediately after cancer treatment, in the case of fertil-
ity preservation, frozen embryos, eggs, and ovarian tissue may not be
used for many years, even decades. However, according to the princi-
ple of moral neutrality, the timing of a harm has no moral signifi-
cance.15 Consequently, the time at which a woman experiences the
harm of iatrogenic infertility-whether it is six months or six years
following treatment-does not change the degree of harm. Further-
more, some iatrogenic conditions do not materialize immediately, but
rather take time to develop (for example, stomach ulcers from
ibuprofen).
Third, when insurance companies cover iatrogenic conditions that
would not be covered when naturally occurring (such as breast sur-
gery and wigs), part of the reason for doing so is that the results of the
treatment, which are visible to both the patient and others, normalizes
the patient's gendered body and identity. Women without certain
gender markers, like breasts or head hair, often feel less feminine,
which affects their sense of self and quality of life. Moreover, others
in society may feel uncomfortable with, and act differently toward, a
woman whose physical appearance does not match the "normal"
female body. Yet, fertility preservation treatment also normalizes
women's gendered body and identity in a visible way. In addition to
the fact that motherhood is an important part of many women's iden-
tity, there is a social expectation that women have children. Preg-
nancy is one of the most visible symbols of femininity, as is a woman
caring for children.
Fourth, fertility preservation treatment is inherently more socially
and ethically complex because it not only affects the individual pa-
tient, but also involves and impacts her current or future partner, her
family (including her parents and current children), and future off-
spring in ways that treatment for other iatrogenic conditions do not.
While fertility preservation treatment is indeed more socially and ethi-
cally complex than other treatments, this difference is not pertinent to
discussions of insurance coverage. Insurance companies often cover
socially and ethically complex procedures outside of ART, including
"corrective" surgery for intersex infants, fetal surgery, and genetic
testing for hereditary diseases. The social and ethical complexity of
the treatment should not factor into coverage decisions, though it may
indicate that patients need extra counseling before making treatment
decisions.
15. JOHN RAWLS, A THEORY OF JUSTICE 403-04 (1971).
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Unlike the first four objections, the last objection does not compare
ART with other covered treatments. Rather, it deals with the appro-
priateness of providing ART to cancer patients because cancer pa-
tients do not meet the definition of infertility. When insurance
companies do cover infertility treatment, it generally only applies to
those diagnosed as infertile, commonly defined as the inability to con-
ceive after one year of regular and unprotected heterosexual inter-
course. Although cancer patients are not infertile at the time when
fertility preservation treatment would take place (right before the
commencement of cancer treatment), for many, infertility is an unfor-
tunate inevitability following some treatments. While it is difficult to
precisely predict a patient's chance of infertility, some treatments gen-
erally yield infertility rates of eighty percent or more. 16 Although it is
true that cancer patients do not fit the standard definition of infertil-
ity, this does not mean that their need for infertility treatment is any
less-in some ways, their need for infertility treatment is greater. Un-
like traditional infertility patients who can continue receiving infertil-
ity treatment until they conceive, cancer patients often only have one
opportunity to preserve their fertility because preservation must occur
before they begin cancer treatment. The unique situation cancer pa-
tients face reveals the traditional definition of infertility as too limited,
for it cannot account for the fertility preservation needs of those with
foreseeable iatrogenic infertility.
IV. CONCLUSION
As the field of oncofertility continues to develop and fertility pres-
ervation options continue to expand, insurance companies will in-
creasingly be confronted with how to handle iatrogenic infertility for
cancer patients. I have argued that ART for cancer patients are simi-
lar to treatments for other iatrogenic conditions that are currently
covered by insurance and thus their exclusion from insurance cover-
age is unjustified. Insurance companies should, for the sake of consis-
tency and fairness, cover fertility preservation treatment for cancer
patients. Given the controversy surrounding reproductive technolo-
gies, this suggestion may be met with fierce opposition. However, it is
time for insurance companies to stop relegating ART to a separate
realm outside of "real" health care, especially when they cover treat-
ment for conditions that could also be perceived as elective. The fact
that insurance companies have begun covering fertility preservation
16. See Stephanie J. Lee et al., American Society of Clinical Oncology Recommendations on
Fertility Preservation in Cancer Patients, 24 J. CLINICAL ONCOLOGY 2917, 2919 tbl.2 (2006).
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treatment for cancer patients gives hope that fertility and infertility
treatments are finally being taken seriously by insurance companies.
Nevertheless, this coverage is done covertly on a case-by-case basis
rather than under a blanket policy, which insinuates that insurance
companies are still not ready to publicly assume financial responsibil-
ity for iatrogenic infertility.
Perhaps a state or federal mandate, modeled after the Women's
Health and Cancer Rights Act, is necessary for insurance companies
to begin openly and universally covering treatment for iatrogenic in-
fertility. Such a mandate would not only symbolize the importance of
fertility preservation treatment and the severity of infertility as a dis-
ease, but also open the door for more discussions between patients
and providers about fertility preservation treatment. Furthermore, a
mandate would allow greater access by patients from lower socioeco-
nomic statuses, patients without insurance, and patients who do not
have advocates to help them secure funding for this technology.
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